Wells Fargo
PVLA

Wells Fargo’s Palvella Therapeutics PVLA Stock Holding History

Wells Fargo’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$726K Sell
5,824
-5,104
-47% -$532K ﹤0.01% 3939
2025
Q4 		$1.14M Buy
10,928
+3,582
+49% +$306K ﹤0.01% 3864
2025
Q3 		$461K Buy
7,346
+3,681
+100% +$164K ﹤0.01% 4366
2025
Q2 		$82.6K Buy
3,665
+3,615
+7,230% +$84.9K ﹤0.01% 5305
2025
Q1 		$1.4K Hold
50
– – ﹤0.01% 6199
2024
Q4 		$600 Sell
50
-10
-17% -$157 ﹤0.01% 6301
2024
Q3 		$995 Hold
60
– – ﹤0.01% 6125
2024
Q2 		$589 Sell
60
-10
-14% -$113 ﹤0.01% 6134
2024
Q1 		$1.02K Buy
70
+10
+17% +$139 ﹤0.01% 6147
2023
Q4 		$867 Sell
60
-12
-17% -$220 ﹤0.01% 6262
2023
Q3 		$1.71K Buy
72
+3
+4% +$64 ﹤0.01% 6115
2023
Q2 		$920 Hold
69
– – ﹤0.01% 6336
2023
Q1 		$5.35K Buy
69
+1
+1% +$116 ﹤0.01% 6035
2022
Q4 		$5.7K Hold
68
– – ﹤0.01% 5732
2022
Q3 		$7K Hold
68
– – ﹤0.01% 5828
2022
Q2 		$10K Sell
68
-6
-8% -$1.09K ﹤0.01% 5765
2022
Q1 		$18K Buy
74
+7
+10% +$1.84K ﹤0.01% 6057
2021
Q4 		$20K Sell
67
-9
-12% -$2.88K ﹤0.01% 6335
2021
Q3 		$32K Hold
76
– – ﹤0.01% 5798
2021
Q2 		$23K Sell
76
-5,601
-99% -$1.23M ﹤0.01% 5847
2021
Q1 		$1.17M Buy
5,677
+3,359
+145% +$734K ﹤0.01% 4142
2020
Q4 		$464K Sell
2,318
-128
-5% -$26.6K ﹤0.01% 4572
2020
Q3 		$405K Buy
2,446
+606
+33% +$138K ﹤0.01% 4503
2020
Q2 		$457K Buy
1,840
+244
+15% +$57.1K ﹤0.01% 4395
2020
Q1 		$291K Buy
1,596
+441
+38% +$111K ﹤0.01% 4436
2019
Q4 		$334K Buy
1,155
+1
+0.1% +$277 ﹤0.01% 4666
2019
Q3 		$315K Buy
1,154
+42
+4% +$16.3K ﹤0.01% 4693
2019
Q2 		$419K Sell
1,112
-69
-6% -$20.6K ﹤0.01% 4505
2019
Q1 		$317K Sell
1,181
-9
-0.8% -$2.14K ﹤0.01% 4591
2018
Q4 		$254K Buy
1,190
+80
+7% +$24.8K ﹤0.01% 4778
2018
Q3 		$497K Sell
1,110
-83
-7% -$36.1K ﹤0.01% 4443
2018
Q2 		$484K Buy
1,193
+243
+26% +$116K ﹤0.01% 4476
2018
Q1 		$518K Sell
950
-83
-8% -$51.4K ﹤0.01% 4358
2017
Q4 		$623K Buy
1,033
+806
+355% +$375K ﹤0.01% 4236
2017
Q3 		$105K Buy
+227
New +$96.9K ﹤0.01% 5214

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo's PVLA Position: Q1 2026 in Review

Wells Fargo reduced its Palvella Therapeutics (PVLA) stake by 47% in Q1 2026, selling an estimated $532K and leaving 5,824 shares worth $726K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

Wells Fargo first reported a position in PVLA in Q3 2017 and has held it in 35 quarters since. The position peaked at $1.17M in Q1 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Wells Fargo held 5,824 shares of Palvella Therapeutics worth $726K as of Q1 2026.
  • Wells Fargo sold 5,104 Palvella Therapeutics shares in Q1 2026, an estimated $532K.
  • Palvella Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3939 holding.
  • Wells Fargo first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • Wells Fargo's Palvella Therapeutics position peaked at $1.17M in Q1 2021.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.